To read the full story, subscribe or sign in.

Daiichi Sankyo makes strides in gene therapy development in joint project

April 17, 2020

HONG KONG – Daiichi Sankyo Co. Ltd., Mitsubishi UFJ Capital Co. Ltd. and Nagoya Institute of Technology have kicked off research on a joint project for a gene therapy that could be applied to the restoration of vision.

BioWorld Deals and M&A Collaboration Research Ocular Gene therapy

Today's news in brief

BioWorld

BioWorld briefs for July 29, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Illustration of dopamine signaling in the brain

New schizophrenia targets challenge trial design

BioWorld

The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...

Regulatory actions for July 27, 2026

BioWorld

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...

AACR D3: ONM-421 shows antigen-independent tumor control

BioWorld Science

At the American Association for Cancer Research’s inaugural Drug Discovery and Development conference (AACR D3), Onconano Medicine Inc. presented preclinical data...